reason report
stori progress multipl phase initi
bottom line aptinyx report number expens slightli
lower expect gave pipelin updat manag
confirm program progress plan note
expect chang regard collabor
allergan mp due op acquisit
deal expect close earli aptinyx current
cash cash equival june
manag believ suffici cover oper
phase data readout
continu believ chanc work advanc
diabet peripher neuropathi dpn base intrigu post-hoc
analys like deep discoveri engin aptinyx
could lead futur pipelin expans pipelin
candid said realiz investor like
wait least late valid data next phase
trial advanc dpn earli fibromyalgia
make minor adjust financi model base print
increas ep estim
reiter outperform pt
next expect phase trial initi advanc
dpn fibromyalgia phase initi
parkinson cognit impair phase data
post-traumat stress disord ptsd phase data
advanc dpn late phase
data fibromyalgia
sum-of-the-part discount
gener share outstand
year price history/av daili volume mil aptx
compani inform svb leerink llc research
revenu mm ep quarterli figur may sum annual total due chang share outstand
pleas refer page import disclosur price chart analyst certif
think still chanc work advanc dpn despit recent fail phase
studi dpn base intrigu post-hoc analysi appear found appropri
target popul advanc dpn also interest poc fibromyalgia second
pain signific market high unmet need demonstr histor
blockbust product neurontin lyrica cymbalta often use off-label variou
chronic pain disord patient switch therapi often new medic welcom
success
one-product stori aptinyx two molecul either start
phase start phase
also strong drug discoveri platform plu librari identifi compound
enabl continu pipelin expans sustain long-term growth
pt base sotp analysi forecast cash flow discount
fail confirm treatment effect observ post-hoc analysi advanc dpn
fail demonstr efficaci chronic pain disord name fibromyalgia
mechan action nmda-modul diseas valid larg in-
new safeti signal nmda-modul emerg
aptinyx fail monet potenti success like partner
aptinyx unsuccess commerci
aptinyx oper activitiesnet compens non- oper asset use oper invest activitieschang market use invest financ activitiesnet chang convert prefer proce common stock use financ equival begin exchang equival end aptinyx inc
aptinyx balanc sheet asset expens current stockhold equitycurr liabilitiesaccount current equitycommon prefer paid-in stockhold liabil stockhold aptinyx inc
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori aptinyx inc aptx
creat bluematrix
pt base sotp analysi forecast cash flow discount rate
risk valuat
fail confirm treatment effect observ post-hoc analysi advanc dpn patient
fail demonstr efficaci chronic pain disord name fibromyalgia
mechan action nmda-modul diseas valid larg in-human studi
new safeti signal nmda-modul emerg
aptinyx fail monet potenti success like partner
aptinyx unsuccess commerci
rate price target histori abbvi inc
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl compar larg
biopharmaceut compani price sale multipl larg cap peer compani stock discount cash
flow dcf appli peer ep revenu multipl use averag larg cap larg molecul therapeut
compani mid-term growth tail risk celg averag consensu
ep multipl appli current ep estim give valu use
revenu multipl similar compani consensu sale appli revenu
estim give valu lastli dcf valuat given wacc termin
cash flow growth rate begin humira biosimilar entri give present valu averag
three method current price target upon complet analysi quarterli result
revisit price target present remain unchang
risk valuat
risk view outlook valuat includ major chang price outlook reimburs
coverag label competit posit humira compani main product risk includ commerci
develop disappoint compani follow-on program inflammatori diseas imbruvica
venclexta expand hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow dividend
reduct forecast ebitda due neg busi trend would place compani capit alloc
strategi dividend growth risk opportun upsid expect includ stronger-than-expect
price volum share humira emerg tangibl demand underappreci element
compani early-to-mid stage pipelin asset potenti label expans opportun late stage opportun
rate price target histori allergan plc
leerink place outperform rate juli
creat bluematrix
pt base deal dynam
risk valuat
unlik instanc deal fail close current unforeseen reason
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
